Use of Axen Forte (Asfarma, Turkey) in Diabetic Adolescents with Neuropathic Symptoms

David Chkhartishvili, George Natriashvili,
Nana Khachapuridze, Nana Geladze 

Department of Child Neurology, Tbilisi State Medical University, Georgia

Efficacy of non-steroidal anti-inflammatory drugs in different systemic diseases of connective tissue, as well as in diabetic neuropathic symptoms, is well established. However, there is little data regarding the use of axen forte (naproxen sodium, 550 mg) in diabetic patients with above complications to relieve the neuropathic symptoms (paresthesia, pain, burning, numbness) in lower extremities. Our aim was to evaluate the efficacy and safety of axen forte in adolescents with diabetes type I, which developed neuropathic symptoms of different (from mild to moderate) severity. For this purpose, we performed clinical and electrophysiologic study of 12 adolescents (16 - 18 y) with newly diagnosed (within 10 days) and long duration (up to 10 years) poorly controlled diabetes, which developed neuropathic symptoms. A control group included 12 adolescents of the same age, duration and severity of diabetes and similar clinical symptoms. After administration of axen forte (275 mg/day) in patients from main group, the intensity and frequency of above neuropathic symptoms were considerably reduced compared to age-matched control subjects. None of patients did show side effects of pharmacological treatment. These data show efficacy of axen forte in diabetic neuropathy.

Keywords:  neuropathic symptoms, diabetic neuropathy, non-steroidal antiinflammatory drugs, nerve conduction study